Fennec Pharmaceuticals financials
$10.80−1.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $21.3M | $1.5M | $0.00 | $170.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $40.9M | $44.4M | $20.0M | $1.4M | $0.00 | $170.0K | $0.00 | $0.00 | $0.00 |
| Gross margin | 91.6% | 93.3% | 94.1% | 94.4% | — | 100.0% | — | — | — |
| Operating income | -$6.3M | $2.6M | -$12.8M | -$22.6M | -$17.2M | -$17.9M | -$13.0M | -$10.4M | -$7.0M |
| Net income | -$9.7M | -$436.0K | -$16.0M | -$23.7M | -$17.3M | -$18.1M | -$12.8M | -$9.9M | -$7.0M |
| Net margin | −21.8% | −0.9% | −75.5% | −1544.9% | — | −10652.4% | — | — | — |
| Diluted EPS | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 | $-0.76 | $-0.64 | $-0.52 | $-0.47 |
| EBITDA | -$6.3M | $2.6M | -$12.8M | -$22.6M | -$17.2M | -$17.9M | -$13.0M | -$10.4M | -$7.0M |
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.2M | -$14.2M | -$15.6M | -$9.1M | -$7.8M | -$3.6M |
| Free cash flow | -$12.5M | $27.0M | -$17.1M | -$18.2M | — | — | — | — | — |
| Diluted shares | 28.6M | 27.3M | 26.6M | 26.3M | 26.0M | 23.7M | 19.9M | 18.9M | 15.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.8M | $26.6M | $13.3M | $23.8M | $21.1M | $30.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $19.5M | $30.9M | $24.9M | $5.0M | $0.00 |
| Total assets | $70.6M | $44.9M | $26.9M | $26.9M | $22.4M | $31.4M |
| Total liabilities | $35.1M | $50.8M | $38.5M | $29.5M | $6.6M | $2.3M |
| Shareholders' equity | $35.5M | -$5.9M | -$11.6M | -$2.6M | $15.8M | $29.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology